WHO Delists Panacea Biotec's Combination Vaccines From Pre-qualified List; Move Comes A Year After Action Against Sanofi's Shantha Unit
This article was originally published in PharmAsia News
MUMBAI - In a stern signal intended to ensure product quality, the World Health Organization delisted combination vaccines made by Indian vaccine maker Panacea Biotec Ltd. from its list of pre-qualified suppliers
You may also be interested in...
Several drug companies are gearing up to go full throttle into the Indian vaccines market with programs that go beyond pushing products and seek to build up public health awareness on a larger scale. GSK, Sanofi, Merck, Novartis and Pfizer are in the fray with local players Serum Institute of India, Bharat Biotech, and Panacea Biotec.
Indian vaccine makers see the latest move to qualify the Indian regulatory system as an opportunity to pump up exports.
India’s Vaccine Giant Serum Institute Sees Yearly Sales At $500 Million Until 2015 From Global Alliance Effort
India’s largest vaccines manufacturer will take a big chunk of the $4.3 billion public-private global commitment to enhance vaccines access set for June this year.